Literature DB >> 16862572

The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia.

Sebastian Francis1, Mamatha Karanth, Guy Pratt, Jane Starczynski, Laura Hooper, Chris Fegan, Chris Pepper, David Valcarcel, Donald W Milligan, Julio Delgado.   

Abstract

BACKGROUND: Infections are a major factor in the clinical course of chronic lymphocytic leukemia (CLL) and account for 30% to 50% of all deaths. The pathogenesis of infections in CLL is related to hypo-gamma-globulinemia, T-cell immune dysfunction, and the immunosuppressive effect of treatment.
METHODS: The authors retrospectively assessed the correlations between new prognostic markers and types of infections encountered, the time taken to develop these infections, and infection-related mortality in 280 unselected patients with CLL.
RESULTS: One hundred patients (36%) had at least 1 major infection (median, 2 major infections; range, 1-8 major infections) over a median follow-up of 67 months. Infections were the most common cause of death, accounting for 51% of all fatalities. Older age (P = .007), clinical Stage B or C disease (P < .001), unmutated immunoglobulin (Ig)VH gene status (P < .001), genetic abnormalities (P < .001), positive CD38 status (P < .001), and type of initial therapy were associated with a significantly shorter time to first infection. Equally, patient age (P < .001), disease stage (P < .001), CD38 expression (P < .001), IgVH mutation status (P < .001), and genetic abnormalities (P = .003) had a significant impact on infection-related mortality.
CONCLUSIONS: Clinical stage at diagnosis, IgVH mutation status, and initial therapy were possible predictors of severe infections in patients with CLL. The current results may help to identify which patients with CLL are at particularly high risk of developing serious infections and, thus, should be considered for Ig or antibiotic prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862572     DOI: 10.1002/cncr.22094

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy.

Authors:  Andrea Visentin; Nicolò Compagno; Francesco Cinetto; Silvia Imbergamo; Renato Zambello; Francesco Piazza; Gianpietro Semenzato; Livio Trentin; Carlo Agostini
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

2.  Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Authors:  Sameer A Parikh; Jose F Leis; Kari G Chaffee; Timothy G Call; Curtis A Hanson; Wei Ding; Asher A Chanan-Khan; Deborah Bowen; Michael Conte; Susan Schwager; Susan L Slager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Cancer       Date:  2015-04-30       Impact factor: 6.860

3.  Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  Kevin J Freise; Aksana K Jones; Doerthe Eckert; Sven Mensing; Shekman L Wong; Rod A Humerickhouse; Walid M Awni; Ahmed Hamed Salem
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

4.  Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study.

Authors:  Maria Chiara Tisi; Stefan Hohaus; Annarosa Cuccaro; Idanna Innocenti; Elena De Carolis; Tommaso Za; Francesco D'Alò; Luca Laurenti; Luana Fianchi; Simona Sica; Maurizio Sanguinetti; Valerio De Stefano; Livio Pagano
Journal:  Haematologica       Date:  2016-11-17       Impact factor: 9.941

5.  Immune failure, infection and survival in chronic lymphocytic leukemia.

Authors:  Kyle R Crassini; O Giles Best; Stephen P Mulligan
Journal:  Haematologica       Date:  2018-07       Impact factor: 9.941

6.  Outcomes in critically ill chronic lymphocytic leukemia patients.

Authors:  Aliénor Xhaard; Loic Epelboin; David Schnell; François Vincent; Vincent Levy; Marion Malphettes; Elie Azoulay; Michaël Darmon
Journal:  Support Care Cancer       Date:  2013-02-15       Impact factor: 3.603

7.  Allogeneic transplantation for chronic lymphocytic leukemia.

Authors:  Luca Laurenti; Michela Tarnani; Patrizia Chiusolo; Federica Sorà; Simona Sica
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-09-07       Impact factor: 2.576

8.  Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.

Authors:  Scott Best; Vi Lam; Tingting Liu; Nur Bruss; Adam Kittai; Olga V Danilova; Susan Murray; Allison Berger; Nathan D Pennock; Evan F Lind; Alexey V Danilov
Journal:  Leukemia       Date:  2020-03-16       Impact factor: 11.528

9.  The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).

Authors:  Jennifer A Whitaker; Sameer A Parikh; Tait D Shanafelt; Neil E Kay; Richard B Kennedy; Diane E Grill; Krista M Goergen; Timothy G Call; Saad S Kendarian; Wei Ding; Gregory A Poland
Journal:  Vaccine       Date:  2021-01-16       Impact factor: 3.641

10.  Upper respiratory tract colonization by gram-negative rods in patients with chronic lymphocytic leukemia: analysis of risk factors.

Authors:  Izabela Korona-Glowniak; Ewelina Grywalska; Beata Chudzik; Agnieszka Bojarska-Junak; Anna Malm; Jacek Rolinski
Journal:  ScientificWorldJournal       Date:  2012-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.